Anbio Biotechnology (NNNN) vs Trinity Biotech (TRIB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Anbio Biotechnology is the larger company by market cap ($202.8 million vs $4.9 million), about 41.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NNNN | TRIB |
|---|---|---|
| Share price | $4.62 | $6.04 |
| Market cap | $202.78M | $4.91M |
| 1-day change | -5.71% | -10.91% |
| YTD return | -84.64% | — |
| 1-year return | -85.09% | — |
| P/E ratio (TTM) | 30.80 | — |
| EPS (TTM) | $0.15 | $-60.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $44.73 | $52.50 |
| 52-week low | $4.55 | $5.01 |
| Distance from 52-week high | -89.67% | -88.50% |
| Average volume | 146.84K | 21.66K |
| Shares outstanding | 43.89M | 813.13K |
| Employees | 27 | 287 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical Devices |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Anbio Biotechnology is about 41.3 times larger than Trinity Biotech by market value ($202.78M vs $4.91M).
- The two companies sit in different sectors: Anbio Biotechnology in Health Care and Trinity Biotech in Healthcare.
About Anbio Biotechnology
NNNN stock →Anbio Biotechnology provides in vitro diagnostics (IVD) products in the European Union, the Asia Pacific, North America, South America, and internationally. The company offers lateral flow immunoassay, fluorescence immunoassay, loop-mediated isothermal amplification, SHA dry chemistry, chemiluminescence immunoassay, and real-time polymerase chain reaction solutions; and SARS-CoV-2 and SARS-CoV-2/Flu A/Flu B antigen rapid test kits.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 27 employees
About Trinity Biotech
TRIB stock →Trinity Biotech plc, together with its subsidiaries, develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Asia, Africa, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detects infectious diseases; sexually transmitted diseases, such as syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, rubella, varicella and other viral pathogens, as well as products for the in-vitro diagnostic measurement of haemoglobin A1c used in the monitoring and diagnosis of diabetes, and identifying those who are at a risk of developing diabetes.
Healthcare · Medical Devices · 287 employees
NNNN vs TRIB FAQ
Which is bigger, Anbio Biotechnology or Trinity Biotech?
Anbio Biotechnology (NNNN) is larger, with a market capitalization of $202.78M compared with $4.91M for Trinity Biotech (TRIB).
Are Anbio Biotechnology and Trinity Biotech in the same industry?
No. Anbio Biotechnology is in the Health Care sector, while Trinity Biotech is in Healthcare.